About Novigenix
Novigenix is a company based in Epalinges (Switzerland) founded in 2014. It operates as a AI-as-a-Service and HealthTech. Novigenix has raised $20 million across 3 funding rounds from investors including European Union and Eurostars. Novigenix has completed 1 acquisition, including Diagnoplex. Novigenix offers products and services including LITOSeek Platform. Novigenix operates in a competitive market with competitors including Veracyte, Geneoscopy, Miroculus, Cajal Neuroscience and InterVenn, among others.
- Headquarter Epalinges, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Novigenix Sa
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20 M (USD)
in 3 rounds
-
Latest Funding Round
$1.97 M (USD), Grant
Apr 07, 2025
-
Investors
European Union
& 1 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Novigenix
Novigenix offers a comprehensive portfolio of products and services, including LITOSeek Platform.
Liquid biopsy platform for immune response analysis provided.
People of Novigenix
Unlock access to complete
Unlock access to complete
Funding Insights of Novigenix
Novigenix has successfully raised a total of $20M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $1.97 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Novigenix
Novigenix has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and Eurostars.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Novigenix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novigenix
Novigenix has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Diagnoplex.
Investment portfolio details for Novigenix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Molecular diagnostics for colorectal cancer detection are developed.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Novigenix
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Novigenix
Detailed financials for Novigenix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novigenix Comparisons
Peer comparison for Novigenix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novigenix
Novigenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Veracyte, Geneoscopy, Miroculus, Cajal Neuroscience and InterVenn, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are developed.
|
|
| Locked | Locked | Locked |
Non-invasive biomarker tests for colorectal cancer are developed.
|
|
| Locked | Locked | Locked |
MicroRNA profiling platform is developed to detect genes in samples.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease drugs are developed through genetic screening and multi-omics.
|
|
| Locked | Locked | Locked |
Provider of an AI-based clinical decision supporting tool for cancer detection and drug development
|
|
| Locked | Locked | Locked |
RNA-based therapies for treating heart diseases are developed.
|
Detailed competitors of Novigenix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novigenix
Complete news archive for Novigenix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novigenix
Novigenix was founded in 2014 and raised its 1st funding round 6 years after it was founded.
Novigenix is headquartered in Epalinges, Switzerland. It is registered at Epalinges, Vaud, Switzerland.
Novigenix is a funded company, having raised a total of $20M across 3 funding rounds to date.
Novigenix is established as a leader in immuno-transcriptomics, focusing on liquid biopsy multi-omic solutions through the LITOSeek AI-RNA analytics platform. The company is dedicated to accelerating early cancer detection and developing effective therapies for improved patient outcomes. Solutions are provided for precision oncology, including biomarker discovery, therapy response prediction, and patient monitoring. The platform integrates immune data with tumor DNA to address challenges in cancer treatment and pharmaceutical innovation. Sectors served include healthcare and biotechnology, with an emphasis on transforming cancer into a manageable chronic disease.
Novigenix's top competitors include Geneoscopy, HAYA Therapeutics and Veracyte.
Novigenix offers LITOSeek Platform.
Novigenix has made 1 acquisition, including Diagnoplex.
Novigenix has 2 investors. Key investors include European Union, and Eurostars.